Skip to content

Impact of Nutritional Supplement Formulation on Knee Discomfort in Endurance-Trained Individuals

Impact of Nutritional Supplement Formulation on Knee Discomfort in Endurance-Trained Individuals

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126913
Enrollment
Unknown
Registered
2026-06-18
Start date
2025-11-07
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee discomfort caused by exercise

Interventions

Group A (Undenatured Type II Collagen,Turmeric Extract, Enzymatically Hydrolyzed Bone Powder):Undenatured Type II Collagen,Turmeric Extract, Enzymatically Hydrolyzed Bone Powder
Group C (Placebo):Maltodextrin
Group B (glucosamine & chondroitin sulfate):Glucosamine Hydrochloride, Chondroitin Sulfate

Sponsors

Nankai University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18-65 years old; 2. BMI: 18.5-30 kg/m²; 3. Exercise habits: at least 3 endurance workouts per week (like running, swimming, cycling) for 3 months or more; 4. Reversible knee discomfort occurring during or after at least 3 months of physical activity; 5. Joint symptoms: Positive on the Single-Leg-Step-Down (SLSD) test; 6. Participants are physically and mentally healthy, with no medical history, physical exam results, or vital signs that would affect the current study.

Exclusion criteria

Exclusion criteria: 1. Diagnosis of knee osteoarthritis or meeting the condition (1) plus any other two of the following: (1) Recurrent knee pain within the past month; (2) Age >= 50 years; (3) Morning stiffness <= 30 minutes; (4) Presence of bone crepitus (sensation) during activity; 2. Knee surgery, trauma, or injection therapy within the past 3 months; 3. History of acute or severe musculoskeletal injury or severe knee joint damage (e.g., ligament rupture or meniscus surgery); 4. Use of NSAIDs, corticosteroids, or joint health supplements (e.g., glucosamine); 5. Pregnancy, lactation, or history of allergy (to intervention components or placebo excipients); 6. History or presence of cardiovascular disease or comorbidities (e.g., heart failure, stroke, diabetes, hypertension, etc.); 7. Unwillingness to discontinue analgesic medications for joints during the study participation period; 8. Vegetarian.

Design outcomes

Primary

MeasureTime frame
Single-Leg Step-Down (SLSD) Test;

Secondary

MeasureTime frame
Oxidative Stress/Antioxidant indicators (superoxide dismutase (SOD), malondialdehyde(MDA));Muscle damage indicators (Creatine Kinase);Inflammation indicators (C-reactive protein (CRP), Interleukin-6 (IL-6), Tumor Necrosis Factor-alp (TNF-a));Visual Analogue Scale (VAS);Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC);Range of Motion;Cartilage metabolism indicators (Cartilage Oligomeric Matrix Protein (COMP) and C-terminal telopeptide of type II collagen (CTX-II));

Countries

China

Contacts

Public ContactShuo Wang

Nankai University

wangshuo@nankai.edu.cn+86 22 8535 8523

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 29, 2026